Abstract:Introduction More than 350 million people worldwide live with chronic viral hepatitis and are thus at risk for severe complications like liver cirrhosis and hepatocellular carcinoma (HCC). To meet the goals of the World Health Organization (WHO) global hepatitis strategy, there is an urgent need for new immunotherapeutic approaches. These are particularly required for chronic hepatitis B virus infection and – B/D coinfection.

Targeting virus-specific CD8+ T cells for treatment of chronic viral hepatitis: from bench to bedside